Approved prescription drug products with therapeutic equivalence evaluations.

[Washington, D.C.?] : U.S. Dept. of Health and Human Services, Public Health Service, Food and Drug Administration, Bureau of Drugs : 1980-

http://hdl.handle.net/2027/mdp.39015072932877

CUMULATIVE SUPPLEMENT 5

AUG'83 - JAN'84



APPROVED PRESCRIPTION DRUG PRODUCTS

WITH THERAPEUTIC EQUIVALENCE EVALUATIONS

4TH EDITION

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES
PUBLIC HEALTH SERVICE
FOOD AND DRUG ADMINISTRATION
NATIONAL CENTER FOR DRUGS AND BIOLOGICS

FOOD AND DRUG ADMINISTRATION
APPROVED PRESCRIPTION DRUG PRODUCTS
WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS
CUMULATIVE SUPPLEMENT

I. PREFACE

This cumulative supplement is one of a series of monthly updates to the Approved Prescription Drug Products with Therapeutic Equivalence Evaluations, 4th Edition, (the List) to cover interim revisions to the annual publication of the List in its entirety. The List is comprised of several parts and some by their nature are identified by the term "list". The cumulative supplements routinely provide updates to two of these lists: The Drug Product List and the DESI Addendum.

The List cannot be used effectively without the current cumulative supplement. Users may wish to place an asterisk (*) in the List to the left of the ingredient(s) in the Drug Product List and the product name in the Addendum to indicate that changes to that entry appear in the cumulative supplement. It is also suggested that earlier cumulative supplements be discarded to avoid possible confusion. In this way, only the List and current cumulative supplement need be referenced.

A. DRUG PRODUCT LIST

The Drug Product List cumulative supplements include the changes made since August 1, 1983. Each subsequent cumulative supplement replaces the previous month's cumulative supplement.

Information in this cumulative supplement follows the format of the Drug Product List. The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Context information on drug products is provided in each cumulative supplement for completeness to assist in locating the proper place in the Drug Product List for the revision. (Strength(s) which already exist in the publication will not be repeated for context.) A page number in parentheses referring to the Drug Product List is located to the right of the ingredient(s).

Additions to the Drug Product List are indicated by new information in the cumulative supplement. Additions new to the current cumulative supplement are indicated by the symbol >ADD> to the left of the line on which new information exists. The >ADD> symbol is dropped in subsequent cumulative supplements for that item.

Deletions from the Drug Product List are indicated by overstruck print in the cumulative supplement. Deletions new to the current cumulative supplement are indicated by the symbol >DLT> (DELETE) to the left of the line containing the overstruck print. The >DLT> symbol is dropped in subsequent cumulative supplements for that item.

A newly approved product is identified by the lozenge (◆) to the right of its strength. This identifier remains throughout all cumulative supplements for this edition.

B. ADDENDUM: DESI Pending List

Information in this cumulative supplement follows the format of the Addendum. Additions and deletions are indicated in the same manner as in the cumulative supplement to the Drug Product List. A change in Current Status of a DESI product is also indicated by an addition and a deletion.

II. SPECIAL NOTES

A. REPORT OF COUNTS FOR THE DRUG PRODUCT LIST

Categories of counts derived from product information in the Drug Product List and from this cumulative supplement are presented. The report includes counts of new molecular entities approved by the agency during the current month.

B. PRODUCTS CONTAINING PHENACETIN

The October 5, 1983, Federal Register (48FR45466) provides the following Summary: "The Food and Drug Administration (FDA) is withdrawing approval of new drug applications or parts of new drug applications that provide for drug products containing phenacetin, except for those drug products that are the subject of a hearing request. The basis of the withdrawal is phenacetin's high potential for misuse and its unfavorable benefit-to-risk ratio when incorporated in analgesic combinations which are then subject to excessive chronic use." The effective date of this withdrawal order is November 4, 1983.

Because the subject products are no longer approved, the cumulative supplement has identified them by deleting the applicable active ingredient headers followed by a reference to this Special Note.

C. THEOPHYLLINE CONTROLLED RELEASE

Two controlled released theophylline tablets are listed as therapeutically equivalent (AB). Because one of these products was recently approved for once-daily dosing, it is important to be aware that the therapeutic equivalence rating was made on the basis of 12-hour dosing intervals. The rating does not apply to once-daily dosing. To date, no data have been submitted upon which the Agency can base a therapeutic equivalence determination among any of the approved theophylline controlled-release products when dosed once-daily.

D. APPLICANT (NAME) CHANGES

Because it is not practical to identify in the cumulative supplement each and every product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name, the cumulation of these transfers and name changes will be identified in this Special Notes section only. Where only partial approved product lines are transferred between applicants, each approved product involved will appear as an applicant name change in the cumulative supplement. The current list of applicant holder changes follows.

APPLICANT (NAME) CHANGES

Former Applicant (Name)	New Applicant (Name)	New Abbreviated Name
STERI-MED INC SUB KETCHUM LABORATORIES INC	QUANTUM PHARMICS LTD	QUANTUM PHARMICS
KETCHUM LABORATORIES INC	QUANTUM PHARMICS LTD	QUANTUM PHARMICS
PROFESSIONAL PHARMACAL DIV STERI-MED INC	OPTOPICS LABORATORIES CORP	OPTOPICS LABS

The reader should consult the above cumulative list each month to become aware of such transfers and changes. By referring to the Applicant Index in the 4th Edition of the APDP, the transferred products can be identified. The reader might wish to flag these products in the List as a reminder that the applicant has been changed.

III. REPORT OF COUNTS FOR THE DRUG PRODUCT LIST

DESCRIPTION OF REPORT

The following report provides summary counts derived from product information in the Drug Product List and the current cumulative supplement. The counts appear in two sections. Section A. refers to the products in the List and Section B. to products in the current cumulative supplement. A new column of data will appear in Section A. each three-month period following July '83. Section A. therefore will provide baseline and quarterly data while Section B. provides monthly activity.

USE OF REPORT

From the data presented under Section B., users should be able to observe such things as (1) newly approved, DESI effective and remarketed drug products which are added to the List; (2) products that are being removed from the List as the result of withdrawal of approval, changes from prescription to over-the-counter status and discontinued marketing of products; and, (3) trends in approval of products as either multisource or single source during each month within the quarter. The report does not reflect category changes from multisource to single source and vice versa. However, the net gain that results from all additions, deletions and category changes is reflected in the quarterly counts for multisource and single source products.

Drug Product Definition

For this report, a drug product is the representation in the Drug Product List of an active moiety (includes molecular entity and its salts, esters and derivatives) either as a single entity or as a combination product, provided in a specific dosage form and strength for a given route of administration marketed by a firm under a particular generic or trade name.

New Molecular Entity

The active moiety has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or part of a combination.

Drug Product Count

This report provides counts in several categories from the list composed of domestically marketed drug products approved for both safety and effectiveness under sections 505 and 507 of the Federal Food, Drug, and Cosmetic Act. Counts of products still pending in the DESI review are not provided. Excluded also are those approved drug products marketed by distributors; those marketed solely abroad; and products now regarded as medical devices, biologics or foods. Also not included in the counts are those duplicate products of a given applicant whose only distinguishing characteristics are items such as package size, inactive ingredient(s), color and alternate manufacturing sites. These various counts are excluded because the Drug Product List itself excludes products from these categories.

REPORT OF COUNTS FOR THE DRUG PRODUCT LIST

A. COUNTS CUMULATIVE BY QUARTERS

CATEGORIES COUNTED	JULY '83 (BASELINE)	OCT '83
DRUG PRODUCTS LISTED	6679	6783
SINGLE SOURCE	1908 (28.6%)	1915 (28.2%)
MULTISOURCE(1)	4771 (71.4%)	4868 (71.8%)
THERAPEUTICALLY EQUIVALENT	3804 (57.0%)	3891 (57.4%)
NOT THERAPEUTICALLY EQUIVALENT	957 (14.3%)	967 (14.3%)
EXCEPTIONS(2)	10 (0.1%)	10 (0.1%)
NEW MOLECULAR ENTITIES APPROVED	-	2
NUMBER OF APPLICANTS	304	310

B. ACTIVITY FOR SUPPLEMENT NUMBER 5

	NOV '83	DEC ' 83	JAN '84	CUMULATIVE
DRUG PRODUCTS ADDED:	43	39	32	114
NEWLY APPROVED	43	39	32	114
DESI EFFECTIVE	0	0	0	0
REMARKETED	0	0	0	0
DRUG PRODUCTS REMOVED:	36	6	2	44
WITHDRAWN APPROVAL	27	0	0	27
RX TO OTC SWITCH	0	0	0	0
DISCONTINUED MARKETING	9	6	2	17
NET GAIN IN DRUG PRODUCTS	7	33	30	70
SINGLE SOURCE PRODUCTS APPROVED	10	9	18	37
MULTISOURCE DRUG PRODUCTS APPROVED	33	30	14	77
NEW MOLECULAR ENTITIES APPROVED:	3	2	1	6
AS THE ENTITY	3	1	1	5
AS A SALT, ESTER OR DERIVATIVE OF THE ENTITY	0	1	0	1

(1) THERAPEUTIC EQUIVALENCE EVALUATIONS PROVIDED ONLY FOR MULTISOURCE PRODUCTS (i.e., AVAILABLE FROM MORE THAN ONE APPLICANT)

(2) AMINO ACID-CONTAINING PRODUCTS OF VARYING COMPOSITION (SEE PAGE I-5 OF THE LIST)

ACETAMINOPHEN; CODEINE PHOSPHATE (PAGE 3-1)

CAPSULE; ORAL
ACETAMINOPHEN W/ CODEINE #3
AA LEMMON 300MG;30MG*
TYLENOL W/ CODEINE NO. 3
AA MCNEIL PHARM 300MG;30MG

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE (PAGE 3-2)

TABLET; ORAL
CODACET
AA HALSEY DRUG 325MG;5MG*
/PERCOCET-5/
PERCOCET

/ACETAMINOPHEN; PHENACETIN; PHENYLPROPANOLAMINE HYDROCHLORIDE; PHENYLTOLOXAMINE CITRATE/(PAGE 3-2)

(ALL PRODUCTS - SEE SPECIAL NOTE B.)

ALBUMIN, IODINATED, I-131, SERUM (PAGE 3-4)

INJECTABLE; INJECTION
/RADIOIODINATED SERUM ALBUMIN (HUMAN) IHSA I 131/
/MALLINCKRODT/ /6.7-250 UCI/ML/

AMINO ACIDS (PAGE 3-6)

INJECTABLE; INJECTION
>ADD> NEOPHAM 6.5%
>ADD> CUTTER-VITRUM 6.5%*

AMINOPHYLLINE (PAGE 3-8)

/LIQUID; ORAL/
SOLUTION; ORAL
AMINOPHYLLINE
AA BAY LABORATORIES 105MG/5ML*
AA ROXANE LABORATORIES 105MG/5ML*

TABLET; ORAL
AMINOPHYLLINE
BD BARR LABORATORIES 100MG*
BD 200MG*
AB VANGARD LABS/M&M 100MG*
AB 200MG*

/AMPHETAMINE SULFATE/(PAGE 3-13)

/CAPSULE; CONTROLLED RELEASE; ORAL
/BENZEDRINE/
/SKAF LABORATORIES/ /15MG/

/TABLET; ORAL/
/BENZEDRINE/
/SKAF LABORATORIES/ /5MG/
/10MG/

AMPICILLIN TRIHYDRATE; PROBENECID (PAGE 3-13)

POWDER FOR RECONSTITUTION; ORAL
POLYCILLIN-PRB
AB BRISTOL LABS/B-M EQ 3.5GM BASE/BOT;1GM/BOT
PROBAMPACIN
AB BIOCRAFT LABS EQ 3.5GM BASE/BOT;1GM/BOT

ASPIRIN; BUTALBITAL (PAGE 3-15)

TABLET; ORAL
AXOTAL
ADRIA LABORATORIES 650MG;50MG*

ASPIRIN; BUTALBITAL; CAFFEINE (PAGE 3-15)

TABLET; ORAL
ASPIRIN AND CAFFEINE W/ BUTALBITAL
AB PUREPAC/KALIPHARMA 325MG;50MG;40MG*
>ADD> BUTALBITAL W/ ASPIRIN & CAFFEINE
>ADD> AB BOOTS LABORATORIES 325MG;50MG;40MG*

/ASPIRIN; BUTALBITAL; CAFFEINE; PHENACETIN/(PAGE 3-15)

(ALL PRODUCTS - SEE SPECIAL NOTE B.)

ASPIRIN; CAFFEINE; DIHYDROCODEINE BITARTRATE (PAGE 3-15)

CAPSULE; ORAL
SYNALGOS-DC
IVES LABS/AMHO 356.4MG;30MG;16MG*

/ASPIRIN; CAFFEINE; PHENACETIN; PROPOXYPHENE HYDROCHLORIDE/ (PAGE 3-15)

(ALL PRODUCTS - SEE SPECIAL NOTE B.)

ASPIRIN; CAFFEINE; PROPOXYPHENE HYDROCHLORIDE (PAGE 3-16)

CAPSULE; ORAL
DARVON COMPOUND-65
AA ELI LILLY INDSTRS/PR 389MG;32.4MG;65MG
PROPOXYPHENE COMPOUND 65
AA LEMMON 389MG;32.4MG;65MG*
SK-65 COMPOUND
AA SK&F LABORATORIES 389MG;32.4MG;65MG*

ASPIRIN; CARISOPRODOL (PAGE 3-16)

TABLET; ORAL
SOMA COMPOUND
WALLACE PHARMS/C-W 325MG;200MG*

ASPIRIN; CARISOPRODOL; CODEINE PHOSPHATE (PAGE 3-16)

TABLET; ORAL
SOMA COMPOUND W/ CODEINE
WALLACE PHARMS/C-W 325MG;200MG;16MG*

ASPIRIN; HYDROCODONE BITARTRATE (PAGE 3-16)

TABLET; ORAL
VICOPRIN
KNOLL PHARMACEUTICAL 500MG;5MG*

ATRACURIUM BESYLATE (PAGE 3-16)

INJECTABLE; INJECTION
TRACRIUM
BURROUGHS WELLCOME 10MG/ML*

AZURESIN (PAGE 3-18)

GRANULE; ORAL
DIAGNEX BLUE
ER SQUIBB AND SONS 2GM/PACKET

BACAMPICILLIN HYDROCHLORIDE (PAGE 3-18)

TABLET; ORAL
SPECTROBID
PFIZER LABS/PFIZER 800MG*

BENTIROMIDE (PAGE 3-19)

SOLUTION; ORAL
CHYMEX
ADRIA LABORATORIES 500MG/7.5ML*

BENZTHIAZIDE (PAGE 3-20)

TABLET; ORAL
PROAQUA
BP REID-PROVIDENT LABS 50MG

BENZTROPINE MESYLATE (PAGE 3-20)

TABLET; ORAL
> ADD > BENZTROPINE MESYLATE
> ADD > BP QUANTUM PHARMICS 0.5MG*
> ADD > BP 1MG*
> ADD > BP 2MG*
COGENTIN
> ADD > BP MS&D/MERCK 0.5MG
> ADD > BP 1MG
> ADD > BP 2MG

BETAMETHASONE VALERATE (PAGE 3-21)

CREAM; TOPICAL
BETAMETHASONE VALERATE
AB E FOUGERA/BYK-GLDN EQ 0.1% BASE*
AB PHARMADERM/BYK-GLDN EQ 0.1% BASE*
BETATREX
AB SAVAGE LABS/BYK-GLDN EQ 0.1% BASE*

LOTION; TOPICAL
BETAMETHASONE VALERATE
AB E FOUGERA/BYK-GLDN EQ 0.1% BASE*
AB PHARMADERM/BYK-GLDN EQ 0.1% BASE*
BETATREX
AB SAVAGE LABS/BYK-GLDN EQ 0.1% BASE*
VALISONE
AB SCHERING EQ 0.1% BASE

OINTMENT; TOPICAL
BETAMETHASONE VALERATE
AB E FOUGERA/BYK-GLDN EQ 0.1% BASE*
AB PHARMADERM/BYK-GLDN EQ 0.1% BASE*
BETATREX
AB SAVAGE LABS/BYK-GLDN EQ 0.1% BASE*
VALISONE
AB SCHERING EQ 0.1% BASE

BROMPHENIRAMINE MALEATE (PAGE 3-22)

TABLET; ORAL
BROMPHENIRAMINE MALEATE
/AA/ /BOLAR PHARMACEUTICAL/ 4MG/

BUPIVACAINE HYDROCHLORIDE; EPINEPHRINE BITARTRATE (PAGE 3-23)

INJECTABLE; INJECTION
MARCAINE HCL W/ EPINEPHRINE
AP BREON LABS/STERLING 0.5%;0.0091MG/ML
AP 0.75%;0.0091MG/ML
SENSORCAINE
AP ASTRA HOSP PHARM 0.5%;0.0091MG/ML*
AP 0.75%;0.0091MG/ML*

BUTABARBITAL SODIUM (PAGE 3-24)

CAPSULE; ORAL
BUTICAPS
>DLT< /MCNEIL LABORATORIES/ /15MG/
>DLT< /30MG/
>DLT< /50MG/
>DLT< /100MG/
>ADD< WALLACE LABS/C-W 15MG
>ADD< 30MG
>ADD< 50MG
>ADD< 100MG

ELIXIR; ORAL
/BUTABARBITAL SODIUM/
/AA/ /WEST-WARD/ /33MG/5ML/
BUTALAN
/AA/ LANNETT 33.3MG/5ML

/CAFFEINE; CARISOPRODOL; CODEINE PHOSPHATE; PHENACETIN/
(PAGE 3-24)

/TABLET; ORAL/
/SOMA COMPOUND W/ CODEINE/
/WALLACE PHARMS/C-W/ /32MG;200MG;16MG;160MG/

/CAFFEINE; CARISOPRODOL; PHENACETIN/(PAGE 3-25)

(ALL PRODUCTS - SEE SPECIAL NOTE B.)

CAFFEINE; ERGOTAMINE TARTRATE (PAGE 3-25)

SUPPOSITORY; RECTAL
CAFERGOT
BR SANDOZ PHARMS/SANDOZ 100MG;2MG
WIGRAINE
BR ORGANON/AKZONA 100MG;2MG*

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE (PAGE 3-26)

SOLUTION; INTRAPERITONEAL
DIALYTE CONCENTRATE W/ DEXTROSE 30% IN PLASTIC CONTAINER
AM MCGAW/AM HOSP 510MG/100ML;30GM/100ML; 200MG/100ML;9.2GM/100ML; 9.6GM/100ML*
510MG/100ML;30GM/100ML; 200MG/100ML;9.4GM/100ML; 11GM/100ML*
DIALYTE CONCENTRATE W/ DEXTROSE 50% IN PLASTIC CONTAINER
AM MCGAW/AM HOSP 510MG/100ML;50GM/100ML 200MG/100ML;9.2GM/100ML; 9.6GM/100ML*
510MG/100ML;50GM/100ML; 200MG/100ML;9.4GM/100ML; 11GM/100ML*

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE (PAGE 3-26)

SOLUTION; INTRAPERITONEAL
DIALYTE W/ DEXTROSE 2.5% IN PLASTIC CONTAINER
AM MCGAW/AM HOSP 26MG/100ML;2.5GM/100ML; 15MG/100ML;560MG/100ML;390MG/100ML*

CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM CITRATE (PAGE 3-27)

INJECTABLE; INJECTION
ISOLYTE E IN PLASTIC CONTAINER
AM MCGAW/AM HOSP 35MG/100ML;30MG/100ML; 74MG/100ML;640MG/100ML; 500MG/100ML;74MG/100ML*

CEFTIZOXIME SODIUM (PAGE 3-30)

INJECTABLE; INJECTION
CEFIZOX
SK&F LABORATORIES EQ 1GM BASE/VIAL*
EQ 2GM BASE/VIAL*

CEFUROXIME SODIUM (PAGE 3-30)

INJECTABLE; INJECTION
ZINACEF
GLAXO — EQ 750MG BASE/VIAL*
EQ 1.5GM BASE/VIAL*

CEPHALOTHIN SODIUM (PAGE 3-31)

INJECTABLE; INJECTION
KEFLIN
AP ELI LILLY — EQ 1GM BASE/VIAL
AP — EQ 2GM BASE/VIAL
SEFFIN
AP GLAXO — EQ 1GM BASE/VIAL*
AP — EQ 2GM BASE/VIAL*
EQ 10GM BASE/VIAL*

>ADD> **CEPHALOTHIN SODIUM; DEXTROSE** (PAGE 3-31)

>ADD> INJECTABLE; INJECTION
>ADD> CEPHALOTHIN SODIUM IN PLASTIC CONTAINER
>ADD> TRAVENOL LABS — EQ 20MG BASE/ML;50MG/ML*
>ADD> EQ 40MG BASE/ML;50MG/ML*

>ADD> **CEPHALOTHIN SODIUM; SODIUM CHLORIDE** (PAGE 3-31)

>ADD> INJECTABLE; INJECTION
>ADD> CEPHALOTHIN SODIUM IN PLASTIC CONTAINER
>ADD> TRAVENOL LABS — EQ 20MG BASE/ML;9MG/ML*
>ADD> EQ 40MG BASE/ML;9MG/ML*

CHLORDIAZEPOXIDE (PAGE 3-33)

CAPSULE, CONTROLLED RELEASE; ORAL
LIBRELEASE
HOFFMANN-LA ROCHE — 30MG*

CHLORDIAZEPOXIDE HYDROCHLORIDE (PAGE 3-33)

CAPSULE; ORAL
CHLORDIAZEPOXIDE HCL
/AB/ /BOOTS PHARMACEUTICAL/ /5MG/
/AB/ /10MG/
/AB/ /25MG/

CHLOROTHIAZIDE (PAGE 3-35)

TABLET; ORAL
CHLOROTHIAZIDE
AB CHELSEA LABORATORIES — 250MG*
AB — 500MG*

CHLOROTHIAZIDE; RESERPINE (PAGE 3-35)

TABLET; ORAL
CHLOROTHIAZIDE AND RESERPINE
BP WEST-WARD — 250MG;0.125MG*
BP — 500MG;0.125MG*

CHLORPHENIRAMINE MALEATE (PAGE 3-36)

TABLET; ORAL
CHLORPHENIRAMINE MALEATE
/AA/ /TOWNE PAULSEN/ /4MG/

CHLORTHALIDONE (PAGE 3-38)

TABLET; ORAL
CHLORTHALIDONE
AB PUREPAC/KALIPHARMA — 50MG*

CHLORZOXAZONE (PAGE 3-39)

TABLET; ORAL
CHLORZOXAZONE
AA PAR PHARMACEUTICAL — 250MG*

CHYMOPAPAIN (PAGE 3-39)

INJECTABLE; INJECTION
>ADD> DISCASE
>ADD> TRAVENOL LABS — 12,500 UNITS/VIAL*

CIMETIDINE (PAGE 3-39)

TABLET; ORAL
TAGAMET
SK&F LAB — 400MG*

CORTICOTROPIN (PAGE 3-43)

INJECTABLE; INJECTION
/REPOSITORY CORTICOTROPIN/
/BC/ /WYETH LABS/AMHO/ /40 UNITS/ML/
/BC/ /80 UNITS/ML/

CYANOCOBALAMIN (PAGE 3-44)

INJECTABLE; INJECTION
DODECAMIN
AP MAURRY BIOLOGICAL 1MG/ML*
REDISOL
/AP/ MS&D/MERCK /0.1MG/ML/
SYTOBEX
/AP/ PARKE DAVIS/W-L /0.1MG/ML/

CYCLOSPORINE (PAGE 3-46)

INJECTABLE; INJECTION
SANDIMMUNE
SANDOZ PHARMS/SANDOZ 50MG/ML*

SOLUTION; ORAL
SANDIMMUNE
SANDOZ PHARMS/SANDOZ 100MG/ML*

CYPROHEPTADINE HYDROCHLORIDE (PAGE 3-46)

TABLET; ORAL
CYPROHEPTADINE HCL
AA DURAMED PHARMS 4MG*

DAPSONE (PAGE 3-47)

TABLET; ORAL
/AVLOSULFON/
/BP/ /AYERST LABS/AMHO/ /25MG/
/BP/ /100MG/
DAPSONE
/BP/ JACOBUS PHARM 25MG
/BP/ 100MG

DESOXIMETASONE (PAGE 3-49)

OINTMENT; TOPICAL
TOPICORT
HOECHST-ROUSSEL 0.25%*

DEXAMETHASONE (PAGE 3-49)

SOLUTION; ORAL
DEXAMETHASONE
ROXANE LABORATORIES 0.5MG/5ML*
DEXAMETHASONE INTENSOL
ROXANE LABORATORIES 0.5MG/0.5ML*

TABLET; ORAL
DECADRON
BP MS&D/MERCK 6MG
DEXAMETHASONE
BP PAR PHARMACEUTICAL 6MG*
BP ROXANE LABORATORIES 6MG*
1MG*

DEXAMETHASONE SODIUM PHOSPHATE (PAGE 3-50)

INJECTABLE; INJECTION
DEXAMETHASONE
>ADD> AP INVENEX LABS/DEXTER EQ 4MG PHOSPHATE/ML*
>ADD> AP EQ 10MG PHOSPHATE/ML*
/HEXADROL PHOSPHATE/
HEXADROL
AP ORGANON/AKZONA EQ 4MG PHOSPHATE/ML
EQ 20MG PHOSPHATE/ML

SOLUTION/DROPS; OPHTHALMIC
DEXAIR
AT PHARMAFAIR EQ 0.1% PHOSPHATE*
DEXAMETHASONE SODIUM PHOSPHATE
AT BARNES-HIND PHARMS EQ 0.1% PHOSPHATE

DEXTROSE; DOPAMINE HYDROCHLORIDE (PAGE 3-53)

INJECTABLE; INJECTION
/DOPAMINE HCL IN DEXTROSE 5%/
DOPAMINE HCL
AP ABBOTT LABORATORIES 5GM/100ML;80MG/100ML
AP 5GM/100ML;160MG/100ML
DOPAMINE HCL IN PLASTIC CONTAINER
AP ABBOTT LABORATORIES 5GM/100ML;80MG/100ML*
AP 5GM/100ML;160MG/100ML*
5GM/100ML;320MG/100ML*

DEXTROSE; HEPARIN SODIUM (PAGE 3-53)

INJECTABLE; INJECTION
HEPARIN SODIUM 20,000 UNITS AND DEXTROSE 5% IN PLASTIC CONTAINER
TRAVENOL LABS 5GM/100ML;4,000 UNITS/100ML*

DIATRIZOATE MEGLUMINE; DIATRIZOATE SODIUM (PAGE 3-57)

INJECTABLE; INJECTION
/DIATRIZOATE MEGLUMINE AND DIATRIZOATE SODIUM/
DIATRIZOATE-60

DIETHYLPROPION HYDROCHLORIDE (PAGE 3-59)

TABLET; ORAL
DIETHYLPROPION HCL
AA CAMALL 25MG*

DIMENHYDRINATE (PAGE 3-60)

INJECTABLE; INJECTION
DIMENHYDRINATE
/AP/ /INTL MEDICATION SYS//50MG/ML/

DIPHENHYDRAMINE HYDROCHLORIDE (PAGE 3-61)

CAPSULE; ORAL
SK-DIPHENHYDRAMINE
/AA/ SK&F LABORATORIES /25MG/

ELIXIR; ORAL
BELIX
AA HALSEY DRUG 12.5MG/5ML*
DIBENIL
AA HR CENCI LABS 12.5MG/5ML*
/SK-DIPHENHYDRAMINE/
/AA/ /SK&F LABORATORIES/ /12.5MG/5ML/

DISULFIRAM (PAGE 3-63)

TABLET; ORAL
DISULFIRAM
BX CHELSEA LABORATORIES 250MG*
BX 500MG*
BX SIDMAK LABORATORIES 250MG*
BX 500MG*

DOXYCYCLINE HYCLATE (PAGE 3-64)

CAPSULE; ORAL
DOXYCYCLINE HYCLATE
AB CHELSEA LABORATORIES EQ 50MG BASE
AB HEATHER DRUG EQ 50MG BASE*
AB EQ 100MG BASE*
AB PAR PHARMACEUTICAL EQ 100MG BASE*
AB PUREPAC/KALIPHARMA EQ 50MG BASE*
AB EQ 100MG BASE*

DOXYCYCLINE HYCLATE (PAGE 3-64)

INJECTABLE; INJECTION
DOXY 100
AP LYPHO-MED EQ 100MG BASE/VIAL*
DOXY 200
AP LYPHO-MED EQ 200MG BASE/VIAL*
DOXYCYCLINE
AP ELKINS-SINN EQ 100MG BASE/VIAL*
AP EQ 200MG BASE/VIAL*
VIBRAMYCIN
AP PFIZER LABS/PFIZER EQ 200MG BASE/VIAL

TABLET; ORAL
DOXYCYCLINE HYCLATE
AB HEATHER DRUG EQ 100MG BASE*

DROPERIDOL; FENTANYL CITRATE (PAGE 3-64)

INJECTABLE; INJECTION
INNOVAR
/JANSSEN PHARMA/ /2.5MG/ML;0.05MG/ML/
JANSSEN PHARMA 2.5MG/ML;EQ 0.05MG BASE/ML

ECHOTHIOPHATE IODIDE (PAGE 3-65)

POWDER FOR RECONSTITUTION; OPHTHALMIC
/ECHODIDE/
/AT/ /ALCON LABORATORIES/ /0.03%/
/AT/ /0.06%/
/AT/ /0.125%/
/AT/ /0.25%/
PHOSPHOLINE IODIDE
/AT/ AYERST LABS/AMHO 0.03%
/AT/ 0.06%
/AT/ 0.125%
/AT/ 0.25%

EPINEPHRINE; LIDOCAINE HYDROCHLORIDE (PAGE 3-66)

INJECTABLE; INJECTION
LIDOCATON
AP PHARMATON/SZ 0.01MG/ML;2%*
AP 0.02MG/ML;2%*

ERGOLOID MESYLATES (PAGE 3-66)

CAPSULE; ORAL
/HYDERGINE/
HYDERGINE LC

ERYTHROMYCIN (PAGE 3-67)

OINTMENT; OPHTHALMIC

	ERYTHROMYCIN		
AT	E FOUGERA/BYK-GLDN	5MG/GM	
AT	PHARMADERM/BYK-GLDN	5MG/GM	
	ILOTYCIN		
AT	DISTA PRODS/LILLY	5MG/GM	

ETOPOSIDE (PAGE 3-74)

INJECTABLE; INJECTION

	VEPESID		
	BRISTOL LABS/B-M	20MG/ML	

FENTANYL CITRATE (PAGE 3-75)

INJECTABLE; INJECTION

	SUBLIMAZE		
	~~/JANSSEN PHARMA/~~	~~/0.05MG/ML/~~	
	JANSSEN PHARMA	EQ 0.05MG BASE/ML	

FLUOCINOLONE ACETONIDE (PAGE 3-76)

CREAM; TOPICAL

>ADD>	FLUOCET		
>ADD> AT	NMC LABORATORIES	0.01%	
>ADD> AT		0.025%	

SOLUTION; TOPICAL

	FLUOCINOLONE ACETONIDE		
>ADD> AT	BAY LABORATORIES	0.01%	

FLUOXYMESTERONE (PAGE 3-77)

TABLET; ORAL

	FLUOXYMESTERONE		
BP	BOLAR PHARMACEUTICAL	2MG	
BP		5MG	
BP		10MG	
BP	COLMED LABORATORIES	10MG	

FUROSEMIDE (PAGE 3-79)

INJECTABLE; INJECTION

	FUROSEMIDE		
AP	NATCON CHEMICAL	10MG/ML	

FUROSEMIDE (PAGE 3-79)

TABLET; ORAL

	FUROSEMIDE		
>ADD> AB	BARR LABORATORIES	40MG	
AB	ROXANE LABORATORIES	20MG	
AB		40MG	
AB	ZENITH LABORATORIES	20MG	
AB		40MG	

GENTAMICIN SULFATE (PAGE 3-79)

CREAM; TOPICAL

	GENTAFAIR		
AT	PHARMAFAIR	EQ 1MG BASE/GM	
	GENTAMICIN SULFATE		
AT	NMC LABORATORIES	EQ 1MG BASE/GM	

INJECTABLE; INJECTION

	GENTAMICIN SULFATE		
AP	ABBOTT LABORATORIES	EQ 60MG BASE/100ML	
AP		EQ 70MG BASE/100ML	
AP		EQ 80MG BASE/100ML	
AP		EQ 90MG BASE/100ML	
AP		EQ 100MG BASE/100ML	
AP		EQ 1.2MG BASE/ML	
AP		EQ 1.4MG BASE/ML	
AP		EQ 1.6MG BASE/ML	
AP		EQ 1.8MG BASE/ML	
AP		EQ 2MG BASE/ML	
AP		EQ 10MG BASE/ML	
AP		EQ 40MG BASE/ML	
AP	LYPHO-MED	EQ 40MG BASE/ML	
	GENTAMICIN SULFATE IN PLASTIC CONTAINER		
AP	ABBOTT LABORATORIES	EQ 60MG BASE/100ML	
AP		EQ 70MG BASE/100ML	
AP		EQ 80MG BASE/100ML	
AP		EQ 90MG BASE/100ML	
AP		EQ 100MG BASE/100ML	
AP		EQ 1.2MG BASE/ML	
AP		EQ 1.4MG BASE/ML	
AP		EQ 1.6MG BASE/ML	
AP		EQ 1.8MG BASE/ML	
AP		EQ 2MG BASE/ML	

OINTMENT; TOPICAL

	GENTAMICIN SULFATE		
AT	THAMES PHARMACAL	EQ 1MG BASE/GM	

GONADOTROPIN, CHORIONIC (PAGE 3-81)

INJECTABLE; INJECTION
/ANTUITRIN 'S'/
/AP/ /PARKE-DAVIS/W-L/ /5,000 UNITS/VIAL/

GRISEOFULVIN, ULTRAMICROCRYSTALLINE (PAGE 3-82)

TABLET; ORAL
FULVICIN P/G 165
AB SCHERING 165MG
FULVICIN P/G 330
AB SCHERING 330MG
GRISACTIN ULTRA
AB AYERST LABS/AMHO 165MG*
AB 330MG*

HEPARIN SODIUM (PAGE 3-83)

INJECTABLE; INJECTION
HEPARIN SODIUM
AP NATCON CHEMICAL 1,000 UNITS/ML*

HEPARIN SODIUM; SODIUM CHLORIDE - IN PLASTIC (PAGE 3-85)

INJECTABLE; INJECTION
>ADD> HEPARIN SODIUM 5000 UNITS IN SODIUM CHLORIDE 0.45%
>ADD> ABBOTT LABORATORIES 100 UNITS/ML;4.5MG/ML*
>ADD> HEPARIN SODIUM 10,000 UNITS IN SODIUM CHLORIDE 0.45%
>ADD> ABBOTT LABORATORIES 10,000 UNITS/100ML;450MG/100ML*
>ADD> HEPARIN SODIUM 12,500 UNITS IN SODIUM CHLORIDE 0.45%
>ADD> ABBOTT LABORATORIES 5,000 UNITS/100ML;450MG/100ML*
>ADD> HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.45%
>ADD> ABBOTT LABORATORIES 5,000 UNITS/100ML;450MG/100ML*
>ADD> 10,000 UNITS/100ML;450MG/100ML*
>ADD> HEPARIN SODIUM 5000 UNITS IN SODIUM CHLORIDE 0.9%
>ADD> ABBOTT LABORATORIES 1,000 UNITS/100ML;900MG/100ML*
>ADD> HEPARIN SODIUM 10,000 UNITS IN SODIUM CHLORIDE 0.9%
>ADD> ABBOTT LABORATORIES 10,000 UNITS/100ML;900MG/100ML*
>ADD> HEPARIN SODIUM 12,500 UNITS IN SODIUM CHLORIDE 0.9%
>ADD> ABBOTT LABORATORIES 5,000 UNITS/100ML;900MG/100ML*
>ADD> HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.9%
>ADD> ABBOTT LABORATORIES 5,000 UNITS/100ML;900MG/100ML*

HOMATROPINE METHYLBROMIDE (PAGE 3-86)

TABLET; ORAL
HOMAPIN-10
/AA/ MISSION PHARMACAL 10MG
/SENS-TENS 'SE'/
/AA/ /LEMMON/ /10MG/

HYDRALAZINE HYDROCHLORIDE (PAGE 3-86)

TABLET; ORAL
HYDRALAZINE HCL
AA PAR PHARMACEUTICAL 100MG*
AA PUREPAC/KALIPHARMA 50MG*

HYDRALAZINE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE; RESERPINE (PAGE 3-87)

TABLET; ORAL
/R-HCTZ-H/
RESERPINE, HYDROCHLOROTHIAZIDE, AND HYDRALAZINE HCL
RESERPINE, HYDRALAZINE HCL, AND HYDROCHLOROTHIAZIDE
BP REID-PROVIDENT LABS 25MG;15MG;0.1MG*

HYDROCHLOROTHIAZIDE; RESERPINE (PAGE 3-89)

TABLET; ORAL
>ADD> RESERPINE AND HYDROCHLOROTHIAZIDE
>ADD> BP CORD LABORATORIES 50MG;0.125MG*

HYDROCHLOROTHIAZIDE; SPIRONOLACTONE (PAGE 3-89)

TABLET; ORAL
SPIRONOLACTONE W/ HYDROCHLOROTHIAZIDE
AB PUREPAC/KALIPHARMA 25MG;25MG*

HYDROCORTISONE (PAGE 3-90)

CREAM; TOPICAL
ELDECORT
/AT/ ELDER PHARMS /0.5%/
HYDROCORTISONE
AT BAY LABORATORIES 1%
AT 2.5%*

LOTION; TOPICAL
/DELACORT/
/AT/ /MERICON INDUSTRIES/ /0.5%/
GLY-CORT
AT HERAN PHARMACEUTICAL 1%
HYDROCORTISONE
AT MERICON INDUSTRIES 0.5%
/AT/ /JOHNE PAULSEN/ /0.5%/

OINTMENT; TOPICAL
HYDROCORTISONE
AT BAY LABORATORIES 1%
AT 2.5%*

HYDROCORTISONE (PAGE 3-90)

/SOLUTION/DROPS; OPHTHALMIC/
/OPTEF/
/UPJOHN/ /0.5%/

HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE (PAGE 3-92)

SOLUTION/DROPS; OTIC
NEO-OTOSOL-HC
AT CARTER-GLOGAU LABS 1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML*

HYDROCORTISONE ACETATE (PAGE 3-93)

CREAM; TOPICAL
HYDROCORTISONE ACETATE
/AT/ /TONNE PAULSEN/ /1%/

LOTION; TOPICAL
DRICORT
/AT/ INGRAM PHARM 0.5%
/HYDROCORTISONE ACETATE/
/AT/ /TONNE PAULSEN/ /0.5%/

/SUSPENSION/DROPS; OPHTHALMIC; OTIC/
/HYDROCORTONE/
/MSD/MERCK/ /2.5%/

HYDROCORTISONE VALERATE (PAGE 3-95)

OINTMENT; TOPICAL
WESTCORT
WESTWOOD PHARMS 0.2%*

HYDROFLUMETHIAZIDE; RESERPINE (PAGE 3-95)

TABLET; ORAL
HYDROFLUMETHIAZIDE AND RESERPINE
BP COLMED LABORATORIES 50MG;0.125MG*

>ADD> HYDROMORPHONE HYDROCHLORIDE (PAGE 3-95)

>ADD> INJECTABLE; INJECTION
>ADD> DILAUDID-HP
>ADD> KNOLL PHARMACEUTICAL 10MG/ML*

HYDROXYZINE HYDROCHLORIDE (PAGE 3-96)

TABLET; ORAL
HYDROXYZINE HCL
AB BARR LABORATORIES 10MG*
AB DANBURY PHARMACAL 10MG*
AB 25MG*
AB 50MG*

HYDROXYZINE PAMOATE (PAGE 3-96)

CAPSULE; ORAL
HYDROXYZINE PAMOATE
AB VANGARD LABS/M&M EQ 25MG HCL*
AB EQ 50MG HCL*

IMIPRAMINE HYDROCHLORIDE (PAGE 3-97)

TABLET; ORAL
/ANTIPRESS/
/BP/ /LEMMON/ /25MG/
/INAVATE/
/AB/ /AH ROBINS/ /25MG/
/AB/ /50MG/
IMIPRAMINE HCL
AB PAR PHARMACEUTICAL 10MG*
AB 25MG*
AB 50MG*

ISOETHARINE HYDROCHLORIDE (PAGE 3-100)

SOLUTION; INHALATION
ISOETHARINE HCL
AN INTL MEDICATION SYS 0.167%
AN ROXANE LABORATORIES 0.167%*
AN TRAVENOL LABS 0.25%*

ISONIAZID (PAGE 3-101)

SYRUP; ORAL
ISONIAZID
AA CAROLINA MED PRODS 50MG/5ML*
RIMIFON
AA HOFFMANN-LA ROCHE 50MG/5ML

KANAMYCIN SULFATE (PAGE 3-102)

INJECTABLE; INJECTION
KANAMYCIN SULFATE
AP INTL MEDICATION SYS EQ 500MG BASE/2ML*
AP EQ 1GM BASE/3ML*

KANAMYCIN SULFATE (PAGE 3-102)

INJECTABLE; INJECTION
KANTREX
/AP/ /BRISTOL LABS/B-M/ /75MG/2ML/
/AP/ /500MG/2ML/
/AP/ /1GM/3ML/
AP BRISTOL LABS/B-M EQ 75MG BASE/2ML
AP EQ 500MG BASE/2ML
AP EQ 1GM BASE/3ML

LIDOCAINE HYDROCHLORIDE (PAGE 3-104)

INJECTABLE; INJECTION
LIDOCATON
AP PHARMATON/SZ 2%*

METHYLTESTOSTERONE (PAGE 3-121)

TABLET; BUCCAL/SUBLINGUAL
METHYLTESTOSTERONE
/BP/ /JOHNE PAULSEN/ /10MG/

METRONIDAZOLE (PAGE 3-122)

INJECTABLE; INJECTION
METRONIDAZOLE
AP ABBOTT LABORATORIES 500MG/100ML*
METRONIDAZOLE IN PLASTIC CONTAINER
AP ABBOTT LABORATORIES 500MG/100ML*
METRO I.V. IN PLASTIC CONTAINER
AP AM MCGAW/AM HOSP 500MG/100ML*

TABLET; ORAL
METRONIDAZOLE
AB PAR PHARMACEUTICAL 250MG*
AB 500MG*

NANDROLONE DECANOATE (PAGE 3-125)

INJECTABLE; INJECTION
NANDROLONE DECANOATE
AO CARTER-GLOGAU 200MG/ML*
AO LEMMON 100MG/ML
50MG/ML
AO LYPHO-MED 100MG/ML*
AO 200MG/ML*
AO MAURRY BIOLOGICAL 100MG/ML*

>ADD> NICOTINE RESIN COMPLEX (PAGE 3-127)

>ADD> GUM, CHEWING; ORAL
>ADD> NICORETTE
>ADD> MERRELL DOW/DOW CHEM EQ 2MG BASE*

NITROGLYCERIN (PAGE 3-128)

INJECTABLE; INJECTION
NITRONAL
AP G POHL-BOSKAMP 5MG/ML*
1MG/ML*
TRIDIL
AM CRITICAL CARE/AHS 0.5MG/ML*

NYSTATIN (PAGE 3-129)

POWDER; ORAL
NILSTAT
LEDERLE LABS/AM CYAN 100%*

TABLET; ORAL
NYSTATIN
AA PAR PHARMACEUTICAL 500,000 UNITS*

TABLET; VAGINAL
NYSTATIN
AT E FOUGERA/BYK-GLDN 100,000 UNITS*
AT PHARMADERM/BYK-GLDN 100,000 UNITS*

OXPRENOLOL HYDROCHLORIDE (PAGE 3-131)

CAPSULE; ORAL
TRASICOR
CIBA/CIBA-GEIGY 20MG*
40MG*
80MG*
160MG*

OXTRIPHYLLINE (PAGE 3-131)

ELIXIR; ORAL
OXTRIPHYLLINE
BAY LABORATORIES 100MG/5ML*

SYRUP; ORAL
CHOLEDYL
AA PARKE-DAVIS/W-L 50MG/5ML
OXTRIPHYLLINE PEDIATRIC
AA BAY LABORATORIES 50MG/5ML*

OXTRIPHYLLINE (PAGE 3-131)

TABLET, ENTERIC COATED; ORAL

	CHOLEDYL		
AB		PARKE-DAVIS/W-L	100MG
AB			200MG
	OXTRIPHYLLINE		
AB		BOLAR PHARMACEUTICAL	100MG*
AB			200MG*

OXYTETRACYCLINE HYDROCHLORIDE (PAGE 3-132)

CAPSULE; ORAL

	OXLOPAR		
/AB/		/PARKE-DAVIS/W-L/	/EQ 250MG BASE/

PENICILLIN V POTASSIUM (PAGE 3-135)

POWDER FOR RECONSTITUTION; ORAL

	UTICILLIN VK		
/AA/		/UPJOHN/	/EQ 125MG BASE/5ML/
/AA/			/EQ 250MG BASE/5ML/

PHENDIMETRAZINE TARTRATE (PAGE 3-138)

TABLET; ORAL

	PHENDIMETRAZINE TARTRATE		
AA		FERNDALE LABS	35MG*

PHENTERMINE HYDROCHLORIDE (PAGE 3-139)

CAPSULE; ORAL

	ADIPEX-P		
AA		LEMMON	37.5MG*
	DAPEX-37.5		
AA		FERNDALE LABS	37.5MG*
	PHENTERMINE HCL		
AA		CAMALL	37.5MG*

POTASSIUM CHLORIDE (PAGE 3-143)

INJECTABLE; INJECTION

	POTASSIUM CHLORIDE		
/AP/		TRAVENOL LABS	/1MEQ/ML/
/AP/			/3MEQ/ML/
/AP/			/4MEQ/ML/

PREDNISOLONE (PAGE 3-145)

TABLET; ORAL

	PREDNISOLONE		
/BX/		/REXALL DRUG/	/5MG/

PREDNISOLONE ACETATE (PAGE 3-146)

INJECTABLE; INJECTION

	FERNISOLONE		
/BP/		/FERNDALE LABS/	/25MG/ML/

PREDNISOLONE SODIUM PHOSPHATE (PAGE 3-147)

SOLUTION/DROPS; OPHTHALMIC

		HYDELTRASOL		
	/AT/		/MSD/MERCK/	/EQ 0.5% PHOSPHATE/
>_DLT_>		**INFLAMASE**		
>_DLT_>	/AT/		/SM&P/PR/COOPERVISN/	/EQ 0.1% BASE/
>_ADD_>		**INFLAMASE MILD**		
>_ADD_>	AT		COOPERVISION PHARMS	EQ 0.11% PHOSPHATE
		INFLAMASE FORTE		
>_DLT_>	/AT/		/SM&P/PR/COOPERVISN/	/EQ 0.8% BASE/
>_ADD_>	AT		COOPERVISION PHARMS	EQ 0.9% PHOSPHATE
		METRETON		
	/AT/		SCHERING	EQ 0.5% PHOSPHATE
		PREDAIR FORTE		
>_ADD_>	AT		PHARMAFAIR	EQ 0.9% PHOSPHATE
		PREDNISOLONE SODIUM PHOSPHATE		
>_DLT_>	/AT/		/BARNES-HIND PHARMS/	/0.125%/
>_DLT_>				/1%/
>_ADD_>	AT		BARNES-HIND PHARMS	EQ 0.11% PHOSPHATE
>_ADD_>	AT			EQ 0.9% PHOSPHATE
>_DLT_>	/AT/		/MAURRY BIOLOGICAL/	/EQ 0.1% BASE/
>_DLT_>	/AT/			/EQ 0.8% BASE/
>_ADD_>	AT		MAURRY BIOLOGICAL	EQ 0.11% PHOSPHATE
>_ADD_>	AT			EQ 0.9% PHOSPHATE

PREDNISONE (PAGE 3-147)

TABLET; ORAL

	PREDNISONE		
BX		DURAMED PHARMS	5MG*
BX			10MG*
BX			20MG*

PROCAINAMIDE HYDROCHLORIDE (PAGE 3-149)

CAPSULE; ORAL

	PROCAN		
/AB/		PARKE-DAVIS/W-L	/250MG/
/AB/			/500MG/

PROPANTHELINE BROMIDE (PAGE 3-153)

TABLET; ORAL
PROPANTHELINE BROMIDE
AA PAR PHARMACEUTICAL 15MG*

PROPOXYPHENE HYDROCHLORIDE (PAGE 3-153)

CAPSULE; ORAL
PROFOXYPHENE HCL
AA RICHLYN LABORATORIES 65MG

PROPYLTHIOURACIL (PAGE 3-154)

TABLET; ORAL
PROPYLTHIOURACIL
/BP/ /MYLAN PHARMS/ /50MG/

PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE (PAGE 3-155)

SYRUP; ORAL
/PSEUDODINE/
/AA/ /BAY LABORATORIES/ /30MG/5ML;1.25MG/5ML/
/TRIACIN/
/AA/ /NATL PHARM MFG/BARRE/30MG/5ML;1.25MG/5ML/
TRIPOSED
HALSEY DRUG 30MG/5ML;1.25MG/5ML*

TABLET; ORAL
>DLT< /TRI-SUDO/
>DLT</AA/ /MD PHARMACEUTICAL/ /60MG;2.5MG/
/TRIPODRINE/
/AA/ /DANBURY PHARMACAL/ /60MG;2.5MG/
TRIPROLIDINE AND PSEUDOEPHEDRINE
AA BOLAR PHARMACEUTICAL 60MG;2.5MG*
/AA/ /WEST-WARD/ /60MG;2.5MG/
TRIPROLIDINE HCL AND PSEUDOEPHEDRINE HCL
AA CHELSEA LABORATORIES 60MG;2.5MG*

QUINIDINE GLUCONATE (PAGE 3-157)

TABLET, CONTROLLED RELEASE; ORAL
QUINIDINE GLUCONATE
>ADD< AB ROXANE LABORATORIES 324MG*

QUINIDINE SULFATE (PAGE 3-157)

TABLET; ORAL
QUINIDINE SULFATE
AB VITARINE/WEST CHEM 300MG*

RESERPINE (PAGE 3-158)

TABLET; ORAL
/RAURINE/
/BP/ /ONEAL JONES&FELDMAN/ /0.25MG/
/VIO-SERPINE/
/BP/ /RONELL LABORATORIES/ /0.1MG/
/BP/ /0.25MG/

SECOBARBITAL SODIUM (PAGE 3-160)

CAPSULE; ORAL
SECOBARBITAL SODIUM
AA LANNETT 50MG
SECONAL SODIUM
AA ELI LILLY 50MG*
AA 100MG*

SELENIUM SULFIDE (PAGE 3-161)

LOTION/SHAMPOO; TOPICAL
SELENIUM SULFIDE
AT BAY LABORATORIES 2.5%*

SILVER SULFADIAZINE (PAGE 3-161)

CREAM; TOPICAL
/SILVER SULFADIAZINE/
SSD

/SITOSTEROL, ALPHA/ (PAGE 3-161)

/SUSPENSION, ORAL/
/CYTELLIN/
/ELI LILLY/ /36MG/5ML/

SODIUM CHLORIDE (PAGE 3-162)

INJECTABLE; INJECTION
SODIUM CHLORIDE 3% IN PLASTIC CONTAINER
TRAVENOL LABS 3GM/100ML*
SODIUM CHLORIDE 5% IN PLASTIC CONTAINER
TRAVENOL LABS 5GM/100ML*

SODIUM POLYSTYRENE SULFONATE (PAGE 3-165)

SUSPENSION; ORAL, RECTAL
SODIUM POLYSTYRENE SULFONATE
AA ROXANE LABORATORIES 15GM/60ML*
SPS
AA CAROLINA MED PRODS 15GM/60ML

SOMATROPIN (PAGE 3-165)

INJECTABLE; INJECTION
ASELLACRIN 2
SERONO LABS 2 IU/VIAL✖
~~/ASELLACRIN/~~
ASELLACRIN 10

SPIRONOLACTONE (PAGE 3-166)

TABLET; ORAL
SPIRONOLACTONE
AB PUREPAC/KALIPHARMA 25MG✖

SULFACETAMIDE SODIUM (PAGE 3-167)

SOLUTION/DROPS; OPHTHALMIC
SODIUM SULFACETAMIDE
~~/AT/ /KETCHUM LABORATORIES/ 10%/~~
~~/AT/ /30%/~~
AT OPTOPICS LABS 10%
AT 30%
SULFACEL-15
~~/AT/ /STERI-MED/KETCHUM/ /15%/~~
AT OPTOPICS LABS 15%
SULFAIR FORTE
AT PHARMAFAIR 30%

TESTOSTERONE (PAGE 3-173)

INJECTABLE; INJECTION
TESTOSTERONE
CARTER-GLOGAU LABS 50MG/ML✖

TETRACYCLINE HYDROCHLORIDE (PAGE 3-174)

CAPSULE; ORAL
TETRACYCLINE HCL
~~/AB/ /LEMMON/ /250MG/~~

TABLET; ORAL
PANMYCIN
~~/AB/~~ UPJOHN ~~/250MG/~~
SUMYCIN
~~/AB/~~ ER SQUIBB AND SONS 250MG

THALLOUS CHLORIDE, TL-201 (PAGE 3-175)

INJECTABLE; INJECTION
THALLOUS CHLORIDE TL 201
MEDI-PHYSICS 2MCI/ML

THEOPHYLLINE (PAGE 3-176)

(FOR CONTROLLED RELEASE PRODUCTS - SEE SPECIAL NOTE C.)

CAPSULE, CONTROLLED RELEASE; ORAL
SOMOPHYLLIN-CRT
BC FISONS 100MG
THEO-24
BC SEARLE/SEARLE PHARMS 100MG✖
200MG✖
300MG✖

ELIXIR; ORAL
>ADD> ELIXOMIN
>ADD> AA HR CENCI LABS 80MG/15ML✖

SOLUTION; ORAL
THEOLAIR
AA RIKER LABS/3M 80MG/15ML
THEOPHYLLINE
AA ROXANE LABORATORIES 80MG/15ML✖

TABLET, CONTROLLED RELEASE; ORAL
THEOCONTIN
BC PURDUE FREDERICK 200MG✖
>DLT> ~~/400MG/~~
THEO-DUR
BC KEY PHARMACEUTICALS 200MG
>ADD> UNIPHYL
>ADD> PURDUE FREDERICK 400MG

THIORIDAZINE HYDROCHLORIDE (PAGE 3-178)

CONCENTRATE; ORAL
THIORIDAZINE HCL
AA CORD LABORATORIES 30MG/ML✖
AA 100MG/ML✖
AA NATL PHARM MFG/BARRE 100MG/ML✖

TABLET; ORAL
MELLARIL
AB SANDOZ PHARMS/SANDOZ 100MG
THIORIDAZINE HCL
AB BARR LABORATORIES 10MG✖
AB 15MG✖
AB 25MG✖
AB 50MG✖
AB 100MG✖
AB BOLAR PHARMACEUTICAL 10MG✖
AB 100MG✖
AB CORD LABORATORIES 10MG✖
AB 15MG✖
AB 25MG✖
AB 50MG✖

THIORIDAZINE HYDROCHLORIDE (PAGE 3-178)

TABLET; ORAL
THIORIDAZINE HCL

AB	DANBURY PHARMACAL	10MG*	
AB		15MG*	
AB		25MG*	
AB		50MG*	
AB	MYLAN PHARMS	100MG*	
AB	PAR PHARMACEUTICAL	10MG*	
AB		15MG*	
AB		25MG*	
AB		50MG*	
AB		100MG*	
AB	ZENITH LABORATORIES	100MG*	

TIMOLOL MALEATE (PAGE 3-179)

TABLET; ORAL
BLOCADREN

	MS&D/MERCK	5MG

TRIAMCINOLONE ACETONIDE (PAGE 3-180)

AEROSOL; INHALATION
/ARISTOCORT/

	/LEDERLE LABS/AM CYAN/0.25MG/INH/	
	AZMACORT	
	WILLIAM H RORER	0.25MG/INH

CREAM; TOPICAL
TRIAMCINOLONE ACETONIDE

AT	BAY LABORATORIES	0.025%*
AT		0.1%*
AT		0.5%*

OINTMENT; TOPICAL
TRIAMCINOLONE ACETONIDE

AT	BAY LABORATORIES	0.025%*
AT		0.1%*
AT		0.5%*

TRIFLUOPERAZINE HYDROCHLORIDE (PAGE 3-183)

TABLET; ORAL
>DLT> /TRIAZINE/
>ADD> TFP

TRIPELENNAMINE HYDROCHLORIDE (PAGE 3-185)

TABLET; ORAL
TRIPELENNAMINE HCL

>DLT> /AA/	/WEST-WARD/	/50MG/	

TRISULFAPYRIMIDINES (PAGE 3-185)

SUSPENSION; ORAL
/GUAD-RANOID/

/AB/	/ELDER PHARMS/	/500MG/5ML/
	/TRISEN/	
/AB/	/BEECHAM LABS/BEECHAM/	500MG/5ML/
	/TRISUREID/	
/AB/	/REID-PROVIDENT LABS//	500MG/5ML/

TABLET; ORAL
/GUADETTS/

/AB/	/ELDER PHARMS/	/500MG/
	/TRIPLE SULFA 2/	
/AB/	/ZENITH LABORATORIES//	500MG/

TROPICAMIDE (PAGE 3-186)

SOLUTION/DROPS; OPHTHALMIC
MYDRIAFAIR

AT	PHARMAFAIR	0.5%*
AT		1%*

/TYBAMATE/(PAGE 3-186)

/CAPSULE; ORAL/
/TYBATRAN/

	/AH ROBINS/	/250MG/
		/350MG/

VITAMIN A PALMITATE (PAGE 3-188)

CAPSULE; ORAL
/SOLVISYN A/

/AA/	/JOHN PAULSEN/	/50,000 UNITS BASE/

WATER FOR INJECTION, STERILE (PAGE 3-189)

LIQUID; N/A
>ADD> STERILE WATER FOR INJECTION IN PLASTIC CONTAINER

>ADD>	AP	INVENEX LABS/DEXTER	100%*

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E (PAGE AD2)

INJECTABLE; INJECTION
MVC PLUS
ASCOT HOSP PHARMS 10MG/ML;0.006MG/ML;0.5 UGM/ML; 1.5MG/ML;20 IU/ML;0.04MG/ML; 4MG/ML;0.4MG/ML;0.36MG/ML; 0.3MG/ML;330 IU/ML;1 IU/ML

BROMPHENIRAMINE MALEATE; PHENYLEPHRINE HYDROCHLORIDE; PHENYLPROPANOLAMINE HYDROCHLORIDE (PAGE AD3)

ELIXIR; ORAL
ELIXIR DIMETAPP
AH ROBINS /4MG/5ML;5MG/5ML;5MG/5ML

TABLET, CONTROLLED RELEASE; ORAL
DIMETAPP
AH ROBINS /12MG;15MG;15MG

CARAMIPHEN EDISYLATE; CHLORPHENIRAMINE MALEATE; ISOPROPAMIDE; IODIDE; PHENYLPROPANOLAMINE HYDROCHLORIDE (PAGE AD3)

CAPSULE, CONTROLLED RELEASE; ORAL
TUSS-ORNADE
SKAF LABORATORIES /20MG;8MG;2.5MG;50MG

SOLUTION; ORAL
TUSS-ORNADE
SKAF LABORATORIES /5MG/5ML;2MG/5ML;0.75/5ML;15MG/5ML

DICYCLOMINE HYDROCHLORIDE (PAGE AD3)

SYRUP; ORAL
BAYCYCLOMINE
BAY LABORATORIES 10MG/5ML

DIPYRIDAMOLE (PAGE AD4)

TABLET; ORAL
DIPYRIDAMOLE
ASCOT HOSP PHARMS 50MG
DURAMED PHARMS 25MG
50MG
75MG
HALSEY DRUG 50MG
SUPERPHARM 50MG

METHANDROSTENOLONE (PAGE AD6)

TABLET; ORAL
METHANDROSTENOLONE
PAR PHARMACEUTICAL /2.5MG/5MG

CURRENT STATUS - INEFFECTIVE

/CARBRITAL/ /PARKE-DAVIS/W-L/
/CARBROMAL; PENTOBARBITAL SODIUM/

/CLISTIN RA/ /MCNEIL PHARM/
/CARBINOXAMINE MALEATE/

DIMETAPP AH ROBINS
BROMPHENIRAMINE MALEATE; PHENYLEPHRINE HYDROCHLORIDE;
PHENYLPROPANOLAMINE HYDROCHLORIDE

ELIXIR DIMETAPP AH ROBINS
BROMPHENIRAMINE MALEATE; PHENYLEPHRINE HYDROCHLORIDE;
PHENYLPROPANOLAMINE HYDROCHLORIDE

/FORHISTAL/ /CIBA/CIBA-GEIGY/
/DIMETHINDENE MALEATE/

METHANDROSTENOLONE PAR PHARMACEUTICAL
METHANDROSTENOLONE

TUSS-ORNADE SK&F LABORATORIES
CARAMIPHEN EDISYLATE; CHLORPHENIRAMINE MALEATE;
ISOPROPAMIDE IODIDE; PHENYLPROPANOLAMINE HYDROCHLORIDE

☆ U.S. GOVERNMENT PRINTING OFFICE: 1984-421-927:207